文献速递神经肿瘤

首创ERK抑制剂乌利塞替尼在丝裂原活化蛋白激酶驱动的儿童低级别胶质瘤模型中显示有前景的活性

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.
PubMed 文献 · Neuro Oncol · 2023-01-01

本研究在反映KIAA1549:BRAF融合和BRAFV600E突变的患者来源儿童低级别胶质瘤模型(DKFZ-BT66和BT40)中,测试了ERK1/2抑制剂乌利塞替尼(BVD-523)单药及联合MEK抑制剂、BH3模拟物或化疗的抗肿瘤活性。乌利塞替尼抑制MAPK通路活性,在BT40中于低纳摩尔浓度降低细胞活力,联合MEK抑制剂或BH3模拟物体外显示抗增殖协同作用,体内可穿透脑肿瘤组织并抑制MAPK通路,小鼠试验中单药和联合治疗减缓肿瘤生长并提高生存。

要点

  • 乌利塞替尼在两种pLGG模型中抑制MAPK通路活性,并在BT40中以低纳摩尔浓度降低细胞活力。
  • 乌利塞替尼联合MEK抑制剂或BH3模拟物体外显示抗增殖协同作用,且在所有测试组合中显示靶向活性。
  • 临床前小鼠试验中,乌利塞替尼单药和联合治疗减缓肿瘤生长并提高生存。

核心结论

  • 这些数据表明乌利塞替尼治疗pLGG具有较高的临床潜力,并强烈支持在目前计划的一项国际I/II期伞式试验中作为单药和联合治疗进行首次临床评估。

研究设计与样本

  • 研究使用反映KIAA1549:BRAF融合和BRAFV600E突变的患者来源pLGG模型(分别为DKFZ-BT66和BT40)进行体外和体内(斑马鱼胚胎和小鼠)疗效测试。

主要发现

  • 乌利塞替尼抑制两种模型中的MAPK通路活性,并在BT40中以临床可达到的低纳摩尔浓度降低细胞活力。
  • 乌利塞替尼与MEK抑制剂或BH3模拟物联合治疗在体外显示强烈的抗增殖协同作用证据。
  • 乌利塞替尼在所有测试组合中显示靶向活性。
  • 体内达到药物充分穿透脑肿瘤组织,浓度高于体外IC50,并降低MAPK通路活性。
  • 在临床前小鼠试验中,乌利塞替尼单药和联合治疗减缓肿瘤生长并提高生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric low-grade gliomas (pLGG) are the most common pediatric central nervous system tumors, with driving alterations typically occurring in the MAPK pathway. The ERK1/2 inhibitor ulixertinib (BVD-523) has shown promising responses in adult patients with mitogen-activated protein kinase (MAPK)-driven solid tumors. METHODS: We investigated the antitumoral activity of ulixertinib monotherapy as well as in combination with MEK inhibitors (MEKi), BH3-mimetics, or chemotherapy in pLGG. Patient-derived pLGG models reflecting the two most common alterations in the disease, KIAA1549:BRAF-fusion and BRAFV600E mutation (DKFZ-BT66 and BT40, respectively) were used for in vitro and in vivo (zebrafish embryos and mice) efficacy testing. RESULTS: Ulixertinib inhibited MAPK pathway activity in both models, and reduced cell viability in BT40 with clinically achievable concentrations in the low nanomolar range. Combination treatment of ulixertinib with MEKi or BH3-mimetics showed strong evidence of antiproliferative synergy in vitro. Ulixertinib showed on-target activity in all tested combinations. In vivo, sufficient penetrance of the drug into brain tumor tissue in concentrations above the in vitro IC50 and reduction of MAPK pathway activity was achieved. In a preclinical mouse trial, ulixertinib mono- and combined therapies slowed tumor growth and increased survival. CONCLUSIONS: These data indicate a high clinical potential of ulixertinib for the treatment of pLGG and strongly support its first clinical evaluation in pLGG as single agent and in combination therapy in a currently planned international phase I/II umbrella trial.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sigaud R, Rösch L, Gatzweiler C, et al. The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. Neuro Oncol. 2023. PMID: 35882450. doi:10.1093/neuonc/noac183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。